Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Abstract Introduction A favorable benefit-risk balance is required to support licensure of biologics, in keeping with regulatory agencies’ evolving recommendations, including the United States Food and Drugs Administration. We present a structured semi-quantitative benefit-risk analysis of MenACYW-T...

Full description

Bibliographic Details
Main Authors: David Neveu, Tamala Mallett Moore, Betzana Zambrano, Aiying Chen, Marie-Laure Kürzinger, Lydie Marcelon, Mandeep Singh Dhingra
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Infectious Diseases and Therapy
Subjects:
Benefit-risk analysis
Quadrivalent meningococcal conjugate vaccine
MenACYW-TT
Immunogenicity
Safety
Online Access:https://doi.org/10.1007/s40121-023-00864-4

Similar Items

Similar Items